LIQUID BIOPSY MARKET ANALYSIS

Liquid Biopsy Market, By Biomarker Type (CTC (Circulating Tumor Cells), ctNA (Circulating Tumor Nucliec Acids), Exosomes), By Sample Type (Blood, Urine, Others), By Disease Indication (Lung Cancer, Gastrointestinal Cancer, Prostate Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Others), By End User (Hospitals, Cancer Institutes, Academic Institutes, Diagnostic Centers), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027

Published In : Feb 2020
Code : CMI1223
Pages :180
Formats :
Excel and PDF
Industry : Clinical Diagnostic

Market News

Global Liquid Biopsy Market: Key Developments

Major players in the market are focused on adopting partnership strategies to expand their product portfolio. For instance, in January 2020, Saga Diagnostics signed agreements with Laboratoires Servier to perform liquid biopsy testing on cancer patients enrolled in clinical studies.

Major players in the market are also focused on presenting their products at major symposiums. For instance, in January 2020, GRAIL, Inc. presented new data from its trial, CCGA, for liquid biopsy at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, which failed to show marked improvement in sensitivity compared with data presented at the symposium in 2019.